SCHEMBL10463333

SCHEMBL10463333

O=C1CCc2cc(-n3ccnc3)ccc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 11/20 1.00
PDE3A Q14432 11/20 1.00
CRBN Q96SW2 5/20 1.00
TBXAS1 P24557 5/20 1.00
TNIK Q9UKE5 2/20 0.63
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
PDE4A P27815 1/20 0.50
MAPK1 P28482 1/20 0.50
CYP2C19 P33261 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
CYP11B1 P15538 2/20 0.48
CYP11B2 P19099 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800784 0.89 CRBN (1.00) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL20777317 0.89 CRBN (1.00) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL9088237 0.80 PDE3B (0.66) PDE3BPDE3ACRBNTBXAS1LMNA
SCHEMBL21247640 0.79 TNIK (1.00) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL9700754 0.78 PDE3B (0.64) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL9700740 0.78 PDE3B (0.64) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL20772789 0.77 CRBN (1.00) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL30800732 0.77 CRBN (1.00) PDE3BPDE3ACRBNTBXAS1TNIK
SCHEMBL28274911 0.76 PDE3B (0.60) PDE3BPDE3ACRBNTBXAS1LMNA
SCHEMBL10464755 0.76 TBXAS1 (1.00) PDE3BPDE3ACRBNTBXAS1TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2025-03-13 US claimed
EP-3679028-A1 DIHYDROQUINOLINONES C4 Therapeutics, Inc. (US) 2020-07-15 EP claimed
CN-111278816-A Dihydroquinolinones C4医药公司 2020-06-12 CN claimed
WO-2019043208-A1 DIHYDROQUINOLINONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO claimed
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
US-12091397-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. 2024-09-17 US disclosed
CN-111278816-B Dihydro quinolinones C4医药公司 2024-03-15 CN disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
US-11401256-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
EP-3679028-A1 DIHYDROQUINOLINONES C4 Therapeutics, Inc. (US) 2020-07-15 EP disclosed
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
CN-111278816-A Dihydroquinolinones C4医药公司 2020-06-12 CN disclosed
WO-2019043208-A1 DIHYDROQUINOLINONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO disclosed
WO-2019043208-A1 DIHYDROQUINOLINONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO disclosed
US-4921862-A Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors SYNTEX (U.S.A.) INC. (US) 1990-05-01 US disclosed
US-4792561-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1988-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091397-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 PDE3B 4238/4885PDE3A 4254/4885CRBN 1/4885
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 PDE3B 4238/4885PDE3A 4254/4885CRBN 1/4885
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 PDE3B 4238/4885PDE3A 4254/4885CRBN 1/4885
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 PDE3B 4238/4885PDE3A 4254/4885CRBN 1/4885
US-11401256-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 PDE3B 4238/4885PDE3A 4254/4885CRBN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.